
    
      HIV-1-infected patients over 65 years old at risk of polymedication HIV-1-infected adults
      aged â‰¥ 65 years who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a regimen
      containing a pharmacokinetic enhancer as ritonavir or cobicistat Evaluate the antiviral
      efficacy of 24 weeks treatment with the fixed dose combination(FDC) of TAF/FTC/BIC
    
  